Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies for inhibiting blood coagulation and methods of use thereof

An antibody, inhibited technology, applied in the field of novel human tissue factor antibodies, can solve the problems of unsuitable anticoagulants, TF-binding antibodies do not have binding affinity, etc., achieve excellent anticoagulant activity, reduce coagulation, and inhibit blood coagulation Effect

Inactive Publication Date: 2005-03-23
GENENTECH INC
View PDF15 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, current TF-binding antibodies have significant disadvantages and are therefore not suitable for use as anticoagulants
For example, currently TF binding antibodies do not have significant binding affinity for optimal anticoagulant activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies for inhibiting blood coagulation and methods of use thereof
  • Antibodies for inhibiting blood coagulation and methods of use thereof
  • Antibodies for inhibiting blood coagulation and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0252] Embodiment 1-Preparation and Transformation of Anti-rhTF Monoclonal Antibody

[0253] Anti-rhTF monoclonal antibody was prepared as follows.

[0254] A. Immunizations and booster vaccinations

[0255] Five female BALB / c mice were immunized with 10 micrograms each of lipidated purified rhTF. Mice were initially sensitized by intraperitoneal injection with Hunter's Titermax adjuvant. Three final boosters were administered with 0.85% sodium chloride. The booster vaccinations were given at 2, 5.5 and 6.5 months after the initial sensitization. All boosters were given intraperitoneally, but the first dose was given subcutaneously. The final booster vaccination of 20 lines was given 3 days before fusion, and 20 micrograms were given.

[0256] B. Fusion of mouse spleen lymphocytes with mouse myeloma cells

[0257] Lymphocytes from the spleen of rhTF-immunized BALB / c mice were fused to X63-Ag8.653 mouse myeloma cells using PEG1500. After exposure to PEG, cells were incub...

Embodiment 2

[0283] Example 2 - Binding activity of antibodies of the invention

[0284] The antibody of the present invention prepared in Example 1 above was used. The rhTF molecule was expressed in E. coli and purified by immunoaffinity chromatography according to standard methods (see Harlow and Lane, supra, Ausubel et al., supra). The association constant (Ka) and dissociation constant (Kd) of the antibody were determined by ELISA and surface cytoplasmic resonance (i.e. BIACore) assay (see for example Harlow and Lane, supra, Ausubel et al., supra; Altschuh et al., Biochemistry, 31:6298 (1992); and the BIACore method disclosed by Pharmacia Biosensors Inc.). For BIACore assays, rhTF was immobilized on a biosensor chip according to the manufacturer's instructions. Each antibody constant was determined at four antibody concentrations (0.125 nM, 0.25 nM, 0.5 nM and 1 nM).

[0285] Protein concentrations were determined by standard assay assays (M.M. Bradford, Analytical Biochemistry, 72:...

Embodiment 3-F

[0287] Example 3-FXa Specific Matrix Assay Analysis

[0288] Typically the experiments described here were performed using rhTF using phosphatidylcholine (0.07 mg / ml) and phosphatidylserine (0.03 mg / ml) in a 70 / 30 w / w ratio in 50 mM Tris-HCl, pH 7.5, 0.1% bovine serum albumin (BSA) lipidation at 37°C for 30 minutes. A stock solution of preformed TF:FVIIa complex was prepared by incubating 5 nM lipidated rhTF and 5 nM FVIIa at 37°C for 30 minutes. TF:FVIIa complexes were aliquoted and stored at -70°C until needed. Purified human factors VII, VIIa and FX were obtained from Enzyme Research Laboratories. The following buffers were used for all FXa and FVIIa assays: 25 mM Hepes NaOH, 5 mM CaCl 2 , 150mM NaCl, 0.1% BSA, pH7.5.

[0289] Monoclonal antibodies were screened for their ability to block TF:VIIa-mediated activation of FX to FXa. Activation of FX is carried out in two sequential steps. In the first step (FX activation), at Ca +2 The conversion of FX to FXa was assaye...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.

Description

[0001] Cross References to Related Applications [0002] This invention claims the priority of U.S. Patent Application No. 09 / 990,586, filed November 21, 2001; this case requests priority of U.S. Provisional Patent Application No. 06 / 343,306, filed October 29, 2001 Right to apply; this case involves US Patent Application No. 09 / 293,854, filed on April 16, 1999; this case is a division of USSN 08 / 814,806 (today, US Patent No. 5,986,065). The disclosures of US Patent Application Nos. 09 / 990,586, 60 / 343,306, 09 / 293,854, and US Patent No. 5,986,065 are individually incorporated herein by reference. technical field [0003] The present invention relates to novel human tissue factor antibodies and the use of the antibodies to inhibit tissue factor-related functions such as blood coagulation, angiogenesis, tumor metastasis, and inflammation. In particular, the present invention relates to novel antibodies that specifically bind native human tissue factor with high affinity and preve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K16/36C07K16/46
CPCC07K16/467C07K2319/00A61K2039/505C07K16/36C07K2317/24A61P29/00A61P35/00A61P7/02C07K16/18
Inventor 焦建安H·C·王E·L·涅韦斯L·A·莫斯克拉
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com